Rivaroxaban (Xarelto) for prevention of CVA and systemic embolism in patients with non-valvular atrium fibrillation

In comparison with vitamin K antagonists, rivaroxaban has a therapeutic added value and its therapeutic value is equal to that of dabigatran in the prevention of CVA and systemic embolism in adult patients with non-valvular atrium fibrillation with one ore more risk factors.